PMID- 37877802
OWN - NLM
STAT- MEDLINE
DCOM- 20240126
LR  - 20240206
IS  - 1932-8737 (Electronic)
IS  - 0160-9289 (Print)
IS  - 0160-9289 (Linking)
VI  - 47
IP  - 1
DP  - 2024 Jan
TI  - Cryoballoon ablation for atrial fibrillation in patients with heart failure and 
      reduced left ventricular ejection fraction: A systematic review and 
      meta-analysis.
PG  - e24177
LID - 10.1002/clc.24177 [doi]
LID - e24177
AB  - The coexistence of atrial fibrillation (AF) with heart failure (HF) is prevalent, 
      leading to severe complications. This review aimed to investigate the success 
      rate and efficacy of cryoballoon ablation (CBA) by measuring the improvement in 
      the New York Heart Association (NYHA) classification and the effect on the left 
      ventricular systolic function in patients with AF accompanied by heart failure 
      with reduced ejection fraction (HFrEF). Electronic databases search included 
      PubMed, Web of Science, and Scopus in January 2023. Outcomes addressed the 
      following: left ventricular ejection fraction (LVEF) improvement, AF recurrence, 
      NYHA classification improvement, and mortality. STATA 17.0 software was used for 
      data analysis. The effect size for the studies was a standard mean difference 
      (SMD) with a 95% confidence interval (CI) for outcomes. Proportion analysis with 
      95% CI was used for freedom from early AF and AF after 2 years and all-cause 
      death. We included six studies, including 1699 HF patients with 365 HFrEF 
      patients. The SMD of postoperative LVEF compared to preoperative LVEF in HFrEF 
      was 0.99 ([95% CI: 0.60, 1.39], p = .00), and for NYHA was -1.12 ([95% CI: -1.36, 
      -0.87], p = .00). The analysis results in HFrEF patients for freedom from AF 
      after 1 year was 65% ([95% CI: 0.55, 0.75], and after 2 years was 39% ([95% CI: 
      0.10, 0.67]). Proportional analysis was conducted for all-cause death, resulting 
      in 3% mortality ([95% CI: -0.01, 0.07]). Cryoablation of AF accompanied by HFrEF 
      appeared safe as it reduced AF recurrence and enhanced clinical outcomes.
CI  - (c) 2023 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.
FAU - Taha, Amira M
AU  - Taha AM
AD  - Faculty of Medicine, Fayoum University, Fayoum, Egypt.
FAU - Hendi, Nada I
AU  - Hendi NI
AUID- ORCID: 0000-0003-1201-0487
AD  - Faculty of Medicine, Ain Shams University, Egypt.
FAU - Elwekel, Ahmed B
AU  - Elwekel AB
AD  - Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
FAU - Atia, Ahmed
AU  - Atia A
AUID- ORCID: 0000-0001-7939-2585
AD  - Faculty of Medicine, Cairo University, Cairo, Egypt.
FAU - Taha, Nouran A
AU  - Taha NA
AD  - MARS-Global, London, UK.
FAU - Shrestha, Abhigan B
AU  - Shrestha AB
AUID- ORCID: 0000-0002-0681-3825
AD  - M Abdur Rahim Medical College, Dinajpur, Bangladesh.
FAU - Elbanna, Mohamed
AU  - Elbanna M
AUID- ORCID: 0000-0003-4386-5322
AD  - Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20231025
PL  - United States
TA  - Clin Cardiol
JT  - Clinical cardiology
JID - 7903272
SB  - IM
MH  - Humans
MH  - *Atrial Fibrillation/complications/diagnosis/surgery
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - *Heart Failure/complications/diagnosis/surgery
MH  - Treatment Outcome
MH  - *Catheter Ablation/methods
PMC - PMC10766134
OTO - NOTNLM
OT  - atrial fibrillation
OT  - cryoablation
OT  - cryoballoon
OT  - cryotherapy
OT  - heart failure
COIS- The authors declare no conflict of interest.
EDAT- 2023/10/25 12:42
MHDA- 2024/01/26 06:43
PMCR- 2023/10/25
CRDT- 2023/10/25 09:53
PHST- 2023/10/05 00:00 [revised]
PHST- 2023/04/18 00:00 [received]
PHST- 2023/10/16 00:00 [accepted]
PHST- 2024/01/26 06:43 [medline]
PHST- 2023/10/25 12:42 [pubmed]
PHST- 2023/10/25 09:53 [entrez]
PHST- 2023/10/25 00:00 [pmc-release]
AID - CLC24177 [pii]
AID - 10.1002/clc.24177 [doi]
PST - ppublish
SO  - Clin Cardiol. 2024 Jan;47(1):e24177. doi: 10.1002/clc.24177. Epub 2023 Oct 25.